In its decanting of the BRUNELLO trial of #remigromig for #diabeticmacularoedema (DME), #MSD seems to have left observers contemplating a glass half empty.
@pharmaphorum.bsky.social
@pharmaphorum.bsky.socialIn its decanting of the BRUNELLO trial of #remigromig for #diabeticmacularoedema (DME), #MSD seems to have left observers contemplating a glass half empty.
@pharmaphorum.bsky.social#MSD's return to the #ophthalmology field after decades of absence, via the #acquisition of #EyeBio in a $3 billion deal in 2024, has been charged up with a positive phase 3 trial in #diabeticmacularoedema (DME).